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Abstract
Background Cost-effectiveness analyses of behavioral
interventions typically use a dichotomous outcome crite-
rion. However, achieving behavioral change is a complex
process involving several steps towards a change in
behavior. Delayed effects may occur after an intervention
period ends, which can lead to underestimation of these
interventions. To account for such delayed effects, inter-
mediate outcomes of behavioral change may be used in
cost-effectiveness analyses. The aim of this study is to
model cognitive parameters of behavioral change into a
cost-effectiveness model of a behavioral intervention.
Methods The cost-effectiveness analysis (CEA) of an
existing dataset from an RCT in which an high-intensity
smoking cessation intervention was compared with a
medium-intensity intervention, was re-analyzed by mod-
eling the stages of change of the Transtheoretical Model
of behavioral change. Probabilities were obtained from
the dataset and literature and a sensitivity analysis was
performed.
Results In the original CEA over the first 12 months, the
high-intensity intervention dominated in approximately
58% of the cases. After modeling the cognitive parameters
to a future 2nd year of follow-up, this was the case in
approximately 79%.
Conclusion This study showed that modeling of future
behavioral change in CEA of a behavioral intervention
further strengthened the results of the standard CEA.
Ultimately, modeling future behavioral change could have
important consequences for health policy development in
general and the adoption of behavioral interventions in
particular.
Keywords Behavior change  Cognitive determinant 
Cost effectiveness  Smoking cessation  Intermediate
outcome
JEL Classification I00  I19  Z00
Introduction
Cost-effectiveness analyses (CEAs) in health care research
and public health are considered an important tool to help
decision-makers to set funding priorities [1, 2]. CEA can be
defined as the comparative analysis of alternative courses of
action in terms of both their costs and consequences and is
designed to improve health [3]. Exploring the cost-effec-
tiveness of a behavioral health intervention, however, has
some methodological implications compared to pharma-
ceutical interventions. Behavioral interventions encourage
individuals to modify their existing behavior and to adopt a
healthier behavior. CEAs of behavioral interventions typi-
cally use a simple dichotomous (success or failure) outcome
criterion [4]. In reality, though, behavioral change is a
complex process in which several steps towards success are
taken. As most intervention studies have a relatively short
follow-up period of 6–12 months, it is likely that effects are
achieved after the follow-up period. In fact, any progress in
behavioral change without accomplishing full behavioral
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change may also be considered as a beneficial outcome of
the intervention [5]. Not accounting for ‘delayed’ behav-
ioral change may lead to underestimation of effectiveness of
behavioral interventions [6–9]. Obviously, extending the
follow-up period would be the preferred way to address this
issue. However, this is often impeded by practical and
financial limitations. An alternative may be to use inter-
mediate outcome measures to model future behavioral
change. In their review on this topic, Wagner and Goldstein
[4] stated that analysts who conduct a CEA of a behavioral
intervention should not focus solely on people who changed
their behavior successfully, but they also need to measure
partial behavioral change. They conclude that failing to
include partial behavioral change in the CEA can bias the
results. Studies on interventions that collect stages of
change data (e.g., the Transtheoretical model of behavioral
change [10]), for example, enable the measurement of
partial behavioral change and the subsequent incorporation
of these as intermediate outcomes into CEAs. Also, non-
stage-based psychological theories can provide measures of
partial behavioral change, such as the Theory of Planned
Behavior from Ajzen [11] and Bandura’s Social Cognitive
Theory [12].
The Transtheoretical model of behavioral change is a
stage-oriented model that describes readiness to change
[13]. Beginning in 1977, Prochaska and colleagues devel-
oped the model, based on an analysis of different theories
of psychotherapy. Nowadays, it has been widely adopted
for numerous health behaviors [10]. A number of qualita-
tively different, discrete states, the ‘stages-of-change’, are
key constructs of the Transtheoretical model. It provides an
algorithm that distinguishes 6 stages; the focus of this study
is on the first three ‘pre-action’ stages: (1) precontempla-
tion (e.g., no intention to quit smoking within the next
6 months); (2) contemplation (e.g., intending to quit
smoking within the next 6 months); and (3) preparation
(e.g., intending to quit smoking within the next 30 days)
[10]. The stage algorithm has been developed on the basis
of empirical findings [14]. These pre-action stages provide
probabilities for the actual transition to the fourth stage, the
‘action stage’, in which full behavioral change is achieved.
The other 2 stages are the ‘maintenance stage’ (in which
people changed their behavior more than 6 months ago)
and the ‘termination stage’ (in which people have achieved
maintenance and no longer experience any temptations and
have full self-control; people may never enter this stage).
Usually, attempts to modify (addictive) behavior are not
immediately successful. With smoking, for example, suc-
cessful quitters make an average of 3 to 4 attempts and go
through a spiral pattern of several cycles before they reach
long-term abstinence. Relapse and recycling through the
stages therefore occur quite frequently as individuals
attempt to modify or cease addictive behaviors [10].
Modeling of partial to future behavioral change has been
applied previously in the CEA literature. For example,
Tengs et al. [15] created the ‘Tobacco Policy Model’ to
estimate cost-effectiveness of school-based anti-tobacco
education over a person’s life-time [15]. They defined and
simulated successfully 3 changes in smoking behavior
using a Markovian computer simulation model: The tran-
sition from never smoked to being a current smoker (ini-
tiation), from current to former smoker (cessation) and
from former to current smoker (relapse). Also for public
health modeling, Mulder et al. [16] applied changes in
smoking status to predict future mortality reduction
through smoking cessation. These are behavioral inter-
mediate outcomes. An alternative may be to use cognitive
parameters. Cognitive parameters are the antecedents of
actual behavioral change, as reported in several behavioral
theories in literature (e.g., Transtheoretical model [13],
Theory of Planned Behavior [11]).
The aim of this study is to model cognitive parameters
into a final cost-effectiveness model of a behavioral inter-
vention to gain more insight into the feasibility and the
challenges involved with this method. For this purpose, we
used an existing dataset and replicated the CEA with
addition of partial behavioral change estimates, based on
the stages-of-change algorithm.
Methods
Sample
Data from the SMOKE study [17, 18] were used. The
SMOKE study is a randomized controlled multi-centre trial
with 1 year follow-up that evaluated the (cost-) effective-
ness of the Smoke Stop Therapy (SST) and the Minimal
Intervention Strategy for Lung patients (LMIS). A total of
234 COPD patients motivated to quit smoking (checked by
their own chest physician) were included in the SMOKE
study and randomly assigned: 117 received the LMIS and
117 patients received the SST. Inclusion criteria were
clinically diagnosed moderate COPD (% predicted
FEV1 = 50–69) or severe COPD (% predicted FEV1\50)
as defined by the American Thoracic Society (ATS) criteria
[19], willingness to participate in a smoking cessation
program, aged between 40 and 75 years, and adequate
knowledge and understanding of the Dutch language. The
only exclusion criterion was a counter indication for the
use of Bupropion (Zyban). The chest physician advised
each smoking COPD patient to quit smoking and, after
providing informed consent, the patient was referred to the
SMOKE study. A total of 9 patients dropped out after
giving informed consent: 6 from the LMIS and 3 from the
SST. At baseline, another 15 patients dropped out: 6 from
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the LMIS and 9 from the SST. These latter patients were
excluded from all analyses. In both conditions, 105 patients
remained for analyses. All missing patients at 12 months
follow-up were assumed to be smokers. All remaining
patients adhered to the counseling sessions.
Baseline characteristics are presented in Table 1. Three
baseline differences were found between groups. Patients
receiving LMIS were older than those receiving the SST
(P \ .05). Nicotine dependence, as measured by the Fag-
erstro¨m questionnaire, was significantly stronger in the
participants allocated to the SST compared to LMIS
(P \ 0.05). In relation to this finding, nicotine addiction, as
indicated by the categorical outcome of the Fagerstro¨m
questionnaire, was also stronger in the SST compared to
the LMIS (P \ 0.01). In a previously published pro-
spective analysis of predictors of quitting in this sample
[18], these 3 baseline characteristics appeared not to be
predictive of validated abstinence at 12 months follow-
up. A bias due to these baseline differences is therefore
unlikely.
SMOKE study
The SMOKE study compares two smoking cessation
interventions in a COPD outpatient setting: the medium-
intensity program LMIS and the high-intensity program
SST. The SST is a multi-component smoking cessation
intervention that consists of group counseling, individual
counseling and telephone contacts, supported by the
obligatory use of Zyban, free of charge. The SST provides
the possibility to repeat the individual sessions after
experiencing a lapse within 3 months. The LMIS is an
existing Dutch intervention that is considered as current
practice for smoking lung patients in the Netherlands [17].
This intervention consists of individual counseling and
telephone contacts. Pharmacological support is recom-
mended during LMIS counseling, but use is voluntary and
at the patients’ cost. The SMOKE study [17] showed the
SST to be cost-effective compared to the LMIS, expressed
as cotinine-validated continuous abstinence rates after
1 year. The number of quitters was 20 in the SST versus 9
in the LMIS, and the associated costs were €3,101 per
quitter in the SST and €6,832 per quitter in the LMIS. The
SST had dominancy over the LMIS on each outcome
parameter in the first 12 months; the SST showed higher
effects and lower costs [17].
Economic evaluation
Decision trees were used to outline the cognitive states and
the pathways a COPD patient could experience, over the
time frame of 12–24 months. They were used to calculate
future behavioral change, the associated costs, and subse-
quently the incremental cost-effectiveness of the SST over
the LMIS. Table 2 shows the base case probabilities with
the associated 95% confidence intervals (CI). They illus-
trate the pathways a COPD patient could experience for
each arm in the decision tree based on data from the
SMOKE study. The primary outcomes are the expected
costs of both interventions per quitter.
Additionally, probabilities were extracted from the data
to determine the distribution in stages-of-change for the
smokers at 12 months. Participants who were abstinent at
12 months were all automatically assigned to the ‘action
stage’, regardless of the duration of their non-smoking
status. For several reasons the ‘maintenance’ and ‘termi-
nation’ stages were not distinguished separately. First, the
time horizon of the model is limited to 12–24 months.
Second, this makes the model more parsimonious and
transparent. Third, differentiating the subjects to more than
4 groups would further increase the confidence intervals of
Table 1 Baseline characteristics of 225 outpatients with COPD,
presented as means (SD) or numbers (%)
Variables Minimal
Intervention
Strategy for
Lung patients
(n = 111)
Smoke
Stop
Therapy
(n = 114)
Gender, male/female 63 (57%)/48
(43%)
55 (48%)/59
(52%)
Age, year* 59.6 (8.51) 57.0 (8.41)
FEVı, L 1.86 (0.85) 1.93 (0.91)
FEVı % predicted of normal 62.8 (25.7) 65.6 (27.4)
IVC, L 4.78 (8.45) 4.71 (7.88)
Cotinine value, ng/ml 292 (144) 324 (145)
Cigarettes daily 20.5 (13.5) 24.1 (13.8)
Pack-years 41.7 (23.9) 46.4 (25.4)
Previous quit attempts ([24 h) 2.89 (5.95) 2.47 (3.38)
Quality of life (SGRQ)
3 domains, range 0–100
Symptoms 52.2 (22.4) 51.4 (22.9)
Activity 55.6 (22.5) 54.6 (23.4)
Impacts 28.6 (16.8) 32.7 (19.8)
Total 40.7 (16.7) 42.5 (19.1)
Depression (BDI), range 0–63 12.1 (8.45) 9.84 (8.37)
Nicotine dependence (Fagerstro¨m),
range 0–10**
4.98 (2.05) 5.84 (2.14)
Nicotine addiction (Fagerstro¨m
score C6), yes/no*
39 (42%)/54
(58%)
58 (59%)/40
(41%)
Education level
High 20 (19%) 13 (13%)
Middle 32 (30%) 30 (31%)
Low 54 (51%) 54 (56%)
* P \ 0.05, ** P \ 0.01
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the probabilities and this would lower the statistical power
with the limited sample size. Participants who reported to
be smokers at 12 months filled in a standardized stage-of-
change questionnaire [20]. Of the smokers in the LMIS,
30.6% (95% CI: 15.6–45.7) were in the pre contemplation
stage, 44.4% (95% CI: 28.2–60.6) were in the contempla-
tion stage and 25% (95% CI: 10.9–39.1) were in the
preparation stage of behavioral change. For the SST these
probabilities were 27.8% (95% CI: 13.2–42.4), 38.9%
(95% CI: 23.0–54.8), and 33.3% (95% CI: 17.9–48.7),
respectively.
Probabilities TTM—weighted average
To predict future behavioral change by the stages of change
as cognitive parameters, probabilities for the transition
from the first 3 ‘pre-action’ stages-of-change to the action
stage (in which the actual desired behavior is performed)
were collected from literature. The preferred time frame for
these probabilities is 12–24 months. A thorough search of
the electronic databases indicated that there are no transi-
tion probabilities available for smoking COPD patients in
this specific time frame. Therefore, a weighted average of
multiple transition probabilities reported in literature was
used. Included were transition probabilities of smoking
cessation interventions, among different populations,
interventions and outcome measures. Studies among ado-
lescents were excluded to limit heterogeneity. The formula
used for calculating the weighted average with numbers
x1; . . .; xn and weights g1; . . .; gn was:
x ¼
Pn
i¼1 gixiPn
i¼1 gi
Table 3 shows the characteristics and probabilities of
the included studies.
Relapse rate
Delayed negative effects of behavioral interventions should
also be taken into account: individuals who relapse into
their old (smoking) behavior after they have reached suc-
cessful behavioral change. An annual relapse rate of 10%
(95% CI: 5–17) for the time frame 12–24 months was
obtained by Hughes et al. [21]. They conducted a meta-
analysis of prospective studies of adult quitters that
reported the number of participants abstinent at 1 year
follow-up and who remained abstinent at C2 years follow-
up (prolonged abstinence). In retrospective datasets of non-
treatment samples, among those abstinent at 1 year, 2–15%
relapsed each year thereafter. The meta-analysis estimated
the incidence of relapse to be 10% per year.
Costs
Costs were based on the costs of the SMOKE study for the
first 12 months follow-up. They were calculated following
a health care perspective, previously reported by Chris-
tenhusz et al. [18]. For 12–24 months follow-up, inter-
vention costs were set to 0. Costs regarding exacerbations
(€101.25) and hospitalizations (€3,140) were included in
the analysis. Because of the different time frames associ-
ated with each stage-of-change, we calculated costs per
Table 2 Base case values of the probabilities in the decision tree for
the Minimal Intervention Strategy for Lung patients (LMIS) and
Smoke Stop Therapy (SST) for the continuous abstinence outcome
measure
N Base case values (95% CI)
LMIS (n = 105)
CA 9 0.086 (0.032–0.14)
CA ? Exa 5 0.556 (0.225–0.887)
CA ? Exa ? Hosp 0 0.000*
CA ? Exa ? no Hosp 5 1.000**
CA ? no Exa 4 0.444 (0.113–0.775)
CA ? no Exa ? Hosp 0 0.000*
CA ? no Exa ? no Hosp 4 1.000**
No CA 96 0.914 (0.86–0.968)
No CA ? Exa 46 0.479 (0.377–0.581)
No CA ? Exa ? Hosp 10 0.217 (0.095–0.339)
No CA ? Exa ? no Hosp 36 0.783 (0.661–0.905)
No CA ? no Exa 50 0.521 (0.419–0.623)
No CA ? no Exa ? Hosp 0 0.000*
No CA ? no Exa ? no Hosp 50 1.000**
SST (n = 105)
CA 20 0.19 (0.113–0.267)
CA ? Exa 12 0.600 (0.381–0.819)
CA ? Exa ? Hosp 1 0.083 (0.000–0.242)
CA ? Exa ? no Hosp 11 0.917 (0.758–0.999)
CA ? no Exa 8 0.400 (0.181–0.619)
CA ? no Exa ? Hosp 0 0.000*
CA ? no Exa ? no Hosp 8 1.000**
No CA 85 0.81 (0.733–0.887)
No CA ? Exa 29 0.341 (0.238–0.444)
No CA ? Exa ? Hosp 4 0.138 (0.01–0.266)
No CA ? Exa ? no Hosp 25 0.862 (0.734–0.99)
No CA ? no Exa 56 0.659 (0.556–0.762)
No CA ? no Exa ? Hosp 0 0.000*
No CA ? no Exa ? no Hosp 56 1.000**
CA Continuous abstinence, n number of participants in each arm, 95%
CI 95% confidence interval, Exa exacerbation, Hosp hospital
admissions, LMIS Minimal Intervention Strategy for Lung patients,
SST SmokeStopTherapy
* The assumption was made that for the actual point values of 0, the
point value was 0.0025
** The assumption was made that for actual point values of 1, the
point value was 0.95
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stage-of-change. For example, the Transtheoretical model
assumes that a smoker in the ‘preparation’ stage will quit
within 1 month. Consequently, this individual will be run
through the model as a smoker during 1 month and
11 months as a quitter. Following this procedure, all costs
in the cost-effectiveness model were adjusted for the dif-
ferent stages of change the participants were in after
12 months follow-up. Costs and effects were not dis-
counted for time preference.
Figure 1 shows the distribution in smoking status and
cognitive states after 12 months of follow-up, the relapse
rates for the second year, the weighted averages for pre-
diction of future behavioral change and their associated
costs for the Smoke Stop Therapy.
Sensitivity analyses
All variables were evaluated for uncertainty into the sen-
sitivity analysis. Uncertainty regarding data inputs was
quantified by means of a Monte Carlo simulation with
1,000 iterations to explore the variation of the total costs as
well as the costs per quitter, and the amount of quitters by
varying the cost parameters and probabilities simulta-
neously over their ranges and the associated 95% confi-
dence intervals. A gamma distribution was assumed for all
costs and a logistic normal distribution for all probabilities.
Sensitivity analyses were performed using @Risk 5.5 for
Excel (Palisade Corporation, 2010; http://www.palisade.
com/).
Results
The total costs of an average COPD patient within the SST
for the 2nd year (12–24 months follow-up) was €99 com-
pared to €301 for the LMIS. The costs generated by sub-
jects of the SST were considerably lower and the SST had a
larger amount of quitters compared to the LMIS. Costs per
quitter generated by the subjects for the LMIS were €2,047
and €413 for the SST. The SST had dominancy over the
LMIS on each outcome parameter over the first 12 months,
and results also show dominancy over 12–24 months.
The weighted averages of the transition probabilities for
the three pre-action stages of change to the action stage
for 12–24 months were: 0.059 (95% CI: 0.035–0.082) for
‘precontemplation’, 0.085 (95% CI: 0.059–0.111) for
‘contemplation’ and 0.118 (95% CI: 0.087–0.149) for the
‘preparation’ stage. Over the period from baseline to
24 months, 25 patients in the SST quit smoking versus 15
patients in the LMIS, which indicated a slightly lower
difference in effect between both interventions compared
to the first 12 months. The total costs per quitter, after
accounting for a 10% relapse rate, were €3,514 and €8,879,
respectively, with a difference of €5,365 in favor of the
Table 3 Characteristics of included studies for the weighted average of transition probabilities stages of change (Transtheoretical model) for
12–24 months
Author Intervention Population N Time
horizon
Outcome
measure
Pre
contemplation
Contemplation Preparation
Carbonari et al. [42] Minimal General smokers 308 12–18 PP 0.130 0.064 0.070
Carbonari et al. [42] Minimal General smokers 308 18–24 PP 0.020 0.058 0.016
Carbonari et al. [42] Minimal General smokers 308 6–12 PP .0100 0.093 0.118
Carbonari et al. [42] Minimal General smokers 308 Time ? 1 PP 0.064 0.084 0.115
DiClemente et al. [43] Minimal Smokers 1,466 0–6 PP 0.079 0.118 0.208
Schumann et al. [50] Stage based General smokers 240 0–12 PP 0.029 0.013 0.004
Schumann et al. [49] No General smokers 786 0–6 PP 0.024 0.100 0.100
Hilberink et al. [45] Yes COPD 244 0–6 PP 0.134 0.167 0.206
Hilberink et al. [45] No COPD 148 0–6 PP 0.080 0.071 0.154
Hilberink et al. [48] Yes COPD 243 0–12 PP 0.082 0.078 0.111
Hilberink et al. [48] No COPD 148 0–12 PP 0.027 NA 0.115
Hilberink et al. [48] Yes COPD 243 0–12 PA 0.010 0.038 0.048
Hilberink et al. [48] None COPD 148 0–12 PA 0.013 NA 0.077
Hilberink et al. [48] Yes COPD 243 0–12 CA 0.010 0.038 0.032
Hilberink et al. [48] No COPD 148 0–12 CA 0.013 NA 0.038
Hennrikus et al. [46] Yes Smoking workers 802 0–24 PA 0.020 0.060 0.110
Farkas et al. [47] No Current smokers 818 0–24 PP 0.070 0.080 0.110
O’Callaghan et al. [44] Yes Smokers 25 0–12 PP 0.030 0.040 NA
PP Point prevalence, PA Prolonged abstinence, CA Continuous abstinence, COPD Chronic obstructive pulmonary disease, NA Not applicable
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SST. Analyses for the point prevalence outcome measure
showed similar outcomes.
Sensitivity analysis of the decision analytic model
Probabilistic sensitivity analysis was employed to analyse
the robustness of the above mentioned findings. The esti-
mates of costs and effects for both the original SMOKE
study and this pilot study are represented graphically in
Fig. 2.
Figure 2 represents the difference in costs associated
with the difference in number of quitters. In almost all
iterations a higher number of quitters is associated with the
SST. In the original SMOKE study [0–12 months; Fig. 2
(left)], the observed costs were, in approximately 58% of
the iterations, lower for the SST than for the LMIS [17].
This rate increased to 84.1% of iterations in favor of SST in
the data generated for 12–24 months in this pilot study
(Fig. 2, right). After simulation, the mean difference
in number of quitters at 2 years is 8.95 (95% CI:
-0.95–18.84), favoring the SST. The mean difference in
total costs between both interventions is €165.21 (95% CI:
-450.73–150.15) and the mean difference in costs per
quitter is €1,505.57 (95% CI: -3,424.20–74.15), also in
favor of the SST. Almost 79% of the iterations are in the
south eastern quadrant of the cost-effectiveness plane,
which indicates the SST to be dominant over the LMIS for
the time frame 12–24 months.
Discussion
Data from the SMOKE study [17] were used to re-analyze
a CEA with addition of partial behavioral change estimates
based on the stages-of-change algorithm. In the time frame
of 12–24 months, the high-intensity smoking cessation
intervention for COPD patients (SST) is more effective and
less costly in approximately 79% of all simulations com-
pared to 58% of the simulations in the 1st year. Thus, the
SST dominates the medium-intensity smoking cessation
intervention (LMIS) even more in this further 2nd year of
follow-up with inclusion of partial behavioral change.
The present paper illustrates a way to integrate psy-
chological theories into the methodology of health eco-
nomic evaluations. As the cost of health care rises and
consequently CEAs become more important, decision
makers have to be optimally informed about the cost-
effectiveness of different treatment options [22]. Inter-
ventions that aim to accomplish behavioral change can
have delayed effects that may influence the cost-
SST
CA
No CA
CA
Relapse
CA
No CA
CA
No CA
CA
No CA
Pre-
contemplation
27,1%
Contemplation
Preparation
38,6%
32,8%
18,6%
81,2%
90,4%
48,44
9,6%
81,99
5,7%
98,77
94,3%
115,55
6,4%
65,22
91,6%
115,55
11,7%
54,03
88,3%
115,55
Fig. 1 Pathways for the
continuous abstinent (CA) and
not continuous abstinent arm of
the Smoke Stop Therapy (SST)
for the time frame
12–24 months, including
percentages and costs (€)
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effectiveness results [23–25]. This suggests that the com-
monly applied follow-up period of 12 months may not be
sufficient to reflect the true, longer term outcomes. Modeling
of partial behavioral change could serve as an alternative
way to include future effects in the cost-effectiveness ratio.
Smith et al. [26] already reported a way to incorporate future
effects by modeling the cognitive ‘pre-action’ stages-of-
change. They included partial behavioral change in their
CEA of a computer-based smoking cessation intervention in
primary care by advancing a smoker’s stage-of-change.
However, no transition probabilities or validation of their
methods were reported. In the present study, we intended to
make the steps that are necessary to model partial behavioral
change more transparent. Consequently, this revealed some
of the methodological and empirical issues that need to be
addressed to further validate this approach.
One of these issues is the predictability of the modeled
cognitive parameters. Obviously, one prerequisite a high
and empirically supported predictive value of these
parameters. Concerning the Transtheoretical model, there
is some debate in the literature about the validity of the
model. Proponents have argued that application of the
model has revolutionized health promotion, but others have
suggested that the problems with the model are so serious
that it has held back advances in the field of health pro-
motion and, despite its intuitive appeal to many practitio-
ners, it should be discarded [27]. However, critique and
debate on the Transtheoretical model is focused mainly on
its supposed usefulness for designing stage-based, tailored
interventions with superior effectiveness [28–30]. It is the
predictive validity of the stages itself that has received
strong empirical support; people who are further along the
continuum are more likely to change their behavior at a
future follow-up point than those who are at an earlier stage
[31, 32]. In literature about the model, these stage effects
appear to be highly consistent [33]. Nevertheless, some
care needs to be taken as our study showed a considerable
variability in transition probabilities reported in literature
(Table 3).
Considering this, is the cure worse than the disease?
Health economic evaluations in general are vulnerable to
manipulation due to the use of primary data and the arbitrary
definition of outcomes. The definition of meaningful outcome
parameters is a precondition for the validity of a study. These
endpoints should be clearly relevant in relation to health
improvement. Predicting full behavioral change after the
intervention period ends, and thus substituting a missing
endpoint, may increase uncertainty compared to using an
observed outcome parameter like, in this case, smoking
cessation. However, uncertainty is pervasive in CEAs [34]
and this is generally accepted. Also, developments in health
behavior research are promising. More and more evidence is
becoming available from theory-based psychological research
to determine the uncertainty that comes with predicting full
behavioral change using cognitive parameters. This applies to
both smoking cessation and other health behaviors. Addi-
tionally, the aim was to show the feasibility and challenges of
incorporating cognitive intermediate outcomes into CEAs of
behavioral interventions. Therefore, no issues regarding dis-
count rates, time dependency or Markov modeling were
taken into account, which would probably result in more
exact estimates of outcomes and reduce uncertainty.
Fig. 2 Monte Carlo simulation results for costs per additional quitter, period 0–12 months (left) and 12–24 months (right). A negative Euro
amount and a positive difference in number of quitters favor the SST. Percentages of simulations in each quadrant are given
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As partial behavioral changes based on the stage effects
of the Transtheoretical model can be incorporated in eco-
nomic evaluations, this may also be valid for other models
of behavioral change [4], such as the Ajzen’s Theory of
Planned Behavior [35, 36] for which ample empirical
support is available. However, this may require other
modeling techniques, like discrete event simulation, as this
theory provides a multidimensional continuum, and no
discrete Markov states.
In this study, the focus was not on the health effects in
the long term, but rather on reducing the risk factor that
exacerbates the disease. For decision makers, however,
future health benefits and costs are more informative than
the costs per quitter following the intervention. The method
presented in this article could therefore serve as an exten-
sion or antecedent of several predictive models for COPD
reported in the literature [37–39], in which disease pro-
gression and death are predicted based on, among other
factors, smoking status.
Quit rates following smoking cessation interventions
have shown to be rather disappointing for the COPD
population. These patients tend to have a long smoking
history, a long history of failed quitting attempts, and a
very strong nicotine addiction [40, 41]. However, transition
probabilities for the pre-action to the action stage-of-
change (TTM) seem not be very different between popu-
lations. Table 3 shows similar probabilities for transitions
for COPD patients and the general population. Therefore,
applying the method presented in this paper to a CEA of an
intervention among the general population will likely show
similar effects.
In conclusion, the results indicate that modeling of
future behavioral change in a CEA of a behavioral inter-
vention in general may lead to a change in results. As the
intervention in the present study was already dominant
over the 1st year and merely became more dominant over
the 2nd year, the observed change in results would not
have led to another decision. In this case, the standard CEA
would have been sufficient for decision makers. However,
in many cases an ICER may turn out to be less favorable or
may approach or even exceed the threshold of willingness-
to-pay. Under such conditions, including partial behavioral
change in the CEA could have a decisive impact. Fur-
thermore, effectiveness data from existing behavioral
interventions that were not assessed with the purpose of
conducting a CEA, are often unsuitable for CEAs due to
variation in the length of follow-up or due to a lack of
adequate behavioral endpoints. Modeling of cognitive
parameters of behavioral change may provide a way to
overcome such variation between studies, by estimating the
required behavioral endpoints for use in CEAs. Ultimately,
modeling future behavioral change can have important
consequences for public health policy development in
general and the adoption of behavioral interventions in
particular.
Acknowledgments This work was supported by the Institute for
Behavioral Research, University of Twente, Enschede, the Nether-
lands and was presented orally at the International Society for Phar-
macoeconomics and Outcomes Research (ISPOR), Paris, 26 October
2009.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C.: Cost-
Effectiveness in Health and Medicine. Oxford University Press,
New York (1996)
2. Brouwer, W., Exel, J.V., Baal, P.V., Polder, J.: Economics and
public health: engaged to be happily married! Eur. J. Public
Health 17(2), 122–123 (2007). doi:10.1093/eurpub/ckl074
3. Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B.J.,
Stoddart, G.L.: Methods for the Economic Evaluation of Health
Care Programmes, 3rd edn. Oxford University Press, New York
(2005)
4. Wagner, T.H., Goldstein, M.K.: Behavioral interventions and
cost-effectiveness analysis. Prev. Med. 39, 1208–1214 (2004).
doi:10.1016/j.ypmed.2004.04.052
5. Velicer, W.F., Martin, R.A., Collins, L.M.: Latent transition
analysis for longitudinal data. Addiction 91 (Suppl.), S197–S209
(1996). doi:10.1111/j.1360-0443.1996.tb02339.x
6. Green, L.W.: Evaluation and measurement: some dilemmas for
health education. Am. J. Public Health 67(2), 155–161 (1977)
7. Martin, R.A., Velicer, W.F., Fava, J.L.: Latent transition analysis
to the stages of change for smoking cessation. Addict. Behav.
21(1), 67–80 (1996). doi:10.1016/0306-4603(95)00037-2
8. Pieterse, M.E., Seydel, E.R., De Vries, H., Mudde, A.N., Kok, G.J.:
Effectiveness of a minimal contact smoking cessation program for
dutch general practitioners: a randomized controlled trial. Prev.
Med. 32, 182–190 (2001). doi:10.1006/pmed.2000.0791
9. Jackson, N., Waters, E.: Criteria for the systematic review of
health promotion and public health interventions. Health Promot.
Int. 20(4), 367–374 (2005). doi:10.1093/heapro/dai022
10. Prochaska, J.O., DiClemente, C.C., Norcross, J.C.: In search of
how people change: applications to addictive behaviors. Am.
Psychol. 47(9), 1102–1114 (1992)
11. Ajzen, I.: The theory of planned behavior. Organ. Behav. Hum.
Decis. Process. 50, 179–211 (1991)
12. Bandura, A.: Social Foundations of Thought and Action: A Social
Cognitive Theory. Prentice Hall, Englewood Cliffs (1986)
13. Prochaska, J.O., DiClemente, C.C.: Stages and processes of self-
change of smoking: toward an integrative model of change.
J. Consult. Clin. Psychol. 51, 390–395 (1983). doi:10.1037/0022-
006X.51.3.390
14. Prochaska, J.O., Velicer, W.F., Rossi, J.S., Goldstein, M.G.,
Marcus, B.H., Rakowski, W., Fiore, C., Harlow, L.L., Redding,
C.A., Rosenbloom, D., Rossi, S.R.: Stages of change and deci-
sional balance for 12 problem behaviors. Health Psychol. 13(1),
39–46 (1994)
15. Tengs, T.O., Osgood, N.D., Chen, L.L.: The cost-effectiveness of
intensive national school-based anti-tobacco education: results
R. Prenger et al.
123
from the tobacco policy model. Prev. Med. 33, 558–570 (2001).
doi:10.1006/pmed.2001.0922
16. Mulder, I., Hoogenveen, R.T., Smit, H.A., De Mesquita, H.B.B.:
Modelling future mortality reduction through smoking cessation
in the European Union. Eur. J. Public Health 14(1), 79–85 (2004).
doi:10.1093/eurpub/14.1.79
17. Christenhusz, L.C.A., Prenger, R., Pieterse, M.E, Seydel, E.R.,
van der Palen, J.: Cost-effectiveness of an intensive smoking
cessation intervention for COPD outpatients. Nicotine Tob. Res.
doi:10.1093/ntr/ntr263
18. Christenhusz, L.C.A., Pieterse, M.E., Seydel, E.R., van der Palen,
J.: Prospective determinants of smoking cessation in COPD patient
within a high intensity or a brief counseling intervention. Patient
Educ. Couns. 66, 162–166 (2007). doi:10.1016/j.pec.2006.11.006
19. Celli, B.R.: ATS standard for the diagnosis and care of patients
with chronic obstructive pulmonary disease. Eur. Respir. Rev. 6,
276–281 (2001)
20. Mudde, A.N., Willemsen, M.C., Kremers, S., de Vries, H.:
Meetinstrumenten voor onderzoek naar roken en stoppen met
roken. STIVORO, Den Haag (2000)
21. Hughes, J.R., Peters, E.N., Naud, S.: Relapse to smoking after
1 year of abstinence: a meta-analysis. Addict. Behav. 33,
1516–1520 (2008). doi:10.1016/j.addbeh.2008.05.012
22. Hanoch, Y., Gummerum, M.: What can health psychologists
learn from health economics: from monetary incentives to
policy programmes. Health Psychol. Rev. 2(1), 2–19 (2008).
doi:10.1080/17437190802311353
23. Vos, T., Haby, M.M., Barendregt, J.J., Kruyshaar, M.E., Corry, J.,
Andrews, G.: The burden of major depression avoidable by
longer-term treatment strategies. Arch. Gen. Psychiatry 61,
1097–1103 (2004). doi:10.1001/archpsyc.61.11.1097
24. Oldenburg, B., Owen, N., Parle, M., Gomel, M.: An economic
evaluation of four work site based cardiovascular risk factor
interventions. Health Educ. Q. 22(1), 9–19 (1995)
25. Gilbody, S., Bower, P., Whitty, P.: Costs and consequences of
enhanced primary care for depression: systematic review of
randomised economic evaluations. Br. J. Psychiatry 189,
297–308 (2006). doi:10.1192/bjp.bp.105.016006
26. Smith, M.Y., Cromwell, J., DePue, J., Spring, B., Redd, W.,
Unrod, M.: Determining the cost-effectiveness of a computer-
based smoking cessation intervention in primary care. Manag.
Care 16(7), 48–55 (2007)
27. West, R.: Time for a change: putting the transtheoretical (stages
of change) model to rest. Addiction 100, 1036–1039 (2005). doi:
10.1111/j.1360-0443.2005.01139.x
28. Prochaska, J.O.: Flaws in the theory or flaws in the study: a
commentary on ‘‘the effect of transtheoretical model based
interventions on smoking cessation’’. Soc. Sci. Med. 68, 404–406
(2009). doi:10.1016/j.socscimed.2008.10.034
29. Riemsma, R.P., Peattenden, J., Bridle, C., Sowden, A.J., Mather,
L., Watt, I.S., Walker, A.: Systematic review of the effectiveness
of stage based interventions to promote smoking cessation. Br.
Med. J. 326, 1175–1177 (2003)
30. Aveyard, P., Massey, L., Parsons, A., Manaseki, S., Griffin, C.:
The effect of transtheoretical model based interventions on
smoking cessation. Soc. Sci. Med. 68, 397–403 (2009). doi:
10.1016/j.socscimed.2008.10.036
31. Hodgins, D.C.: Weighing the pros and cons of changing change
models: a comment on West (2005). Addiction 100, 1042–1043
(2005). doi:10.1111/j.1360-0443.2005.01170.x
32. Dijkstra, A., Roijackers, J., De Vries, H.: Smokers in four stages
of readiness to change. Addict. Behav. 23(3), 339–350 (1998).
doi:10.1016/S0306-4603(97)00070-1
33. Sutton, S.: Another nail in the coffin of the transtheoretical
model? A comment on West (2005). Addiction 100, 1043–1046
(2005). doi:10.1111/j.1360-0443.2005.01172.x
34. Bojke, L., Claxton, K., Sculpher, M., Palmer, S.: Characterizing
structural uncertainty in decision analytic models: a review and
application of methods. Value Health 12(5), 739–749 (2009). doi:
10.1111/j.1524-4733.2008.00502.x
35. Armitage, C.J., Conner, M.: Efficacy of the theory of planned
behaviour: a meta-analytic review. Br. J. Soc. Psychol. 40,
471–499 (2001). doi:10.1348/014466601164939
36. Rise, J., Kovac, V., Kraft, P., Moan, I.S.: Predicting the intention
to quit smoking and quitting behaviour: extending the theory of
planned behaviour. Br. J. Health Psychol. 13(2), 291–310 (2008).
doi:10.1348/135910707X187245
37. Hoogendoorn, M., Rutten-van Mo¨lken, M.P.M.H., Hoogenveen,
R.T., van Genugten, M.L.L., Buist, A.S., Wouters, E.F.M.,
Feenstra, T.L.: A dynamic population model of disease progres-
sion in COPD. Eur. Respir. J. 26, 223–233 (2005). doi:
10.1183/09031936.05.00122004
38. Schembri, S., Anderson, W., Morant, S., Winter, J., Thompson,
P., Pettitt, D., MacDonald, T.M., Winter, J.H.: A predictive
model of hospitalisation and death from chronic obstructive
pulmonary disease. Respir. Med. 103, 1461–1467 (2009). doi:
10.1016/j.rmed.2009.04.021
39. Spencer, M., Briggs, A.H., Grossman, R.F., Rance, L.: Devel-
opment of an economic model to assess the cost effectiveness of
treatment interventions for chronic obstructive pulmonary dis-
ease. Pharmacoeconomics 23(6), 619–637 (2005). doi:10.2165/
00019053-200523060-00008
40. Jime´nez-Ruiz, C.A., Masa, F., Miravitlles, M., Gabriel, R., Viejo,
J.L., Villasante, C., et al.: Smoking characteristics: differences in
attitudes and dependence between healthy smokers and smokers
with COPD. Chest 119(5), 1365–1370 (2001). doi:10.1378/
chest.119.5.1365
41. Tashkin, D., Kanner, R., Bailey, W., Buist, S., Anderson, P.,
Nides, M., et al.: Smoking cessation in patients with chronic
obstructive pulmonary disease: a double-blind, placebo-con-
trolled, randomised trial. Lancet 357(9268), 1571–1575 (2001).
doi:10.1016/s0140-6736(00)04724-3
42. Carbonari, J.P., DiClemente, C.C., Sewell, K.B.: Stage transitions
and the transtheoretical ‘stages of change’ model of smoking
cessation. Swiss J. Psychol. 58(2), 134–144 (1999). doi:10.1024//
1421-0185.58.2.134
43. DiClemente, C.C., Prochaska, J.O., Fairhurst, S.K., Velicer, W.F.,
Velasquez, M.M., Rossi, J.S.: The process of smoking cessation:
an analysis of precontemplation, contemplation, and preparation
stages of change. J. Consult. Clin. Psychol. 59(2), 295–304
(1991). doi:10.1037//0022-006X.59.2.295
44. Callaghan, R.C., Herzog, T.A.: The relation between processes-
of-change and stage-transition in smoking behavior: a two-year
longitudinal test of the transtheoretical model. Addict. Behav. 31,
1331–1345 (2006). doi:10.1016/j.addbeh.2005.10.011
45. Hilberink, S.R., Jacobs, J.E., Bottema, B.J.A.M., de Vries, H.,
Grol. R.P.T.M.: Smoking cessation in patients with COPD in
daily general practice (SMOCC): six months’ results. Prev. Med.
41, 822–827 (2005). doi:10.1016/j.ypmed.2005.08.003
46. Hennrikus, D.J., Jeffery, R.W., Lando, H.A.: The smoking
cessation process: longitudinal observations in a working popu-
lation. Prev. Med. 24, 235–244 (1995). doi:10.1006/pmed.1995.
1039
47. Farkas, A.J., Pierce, J.P., Zhu, S.-H., Rosbrook, B., Gilpin, E.A.,
Berry, C., Kaplan, R. M.: Addiction versus stages of change
models in predicting smoking cessation. Addiction 91,
1271–1280 (1996). doi: 10.1046/j.1360-0443.1996.91912713.x
48. Hilberink, S.R., Jacobs, J.E., Breteler, M.H.M., Grol, R.P.T.M.,
de Vries, H.: Smoking cessation of patients with COPD in daily
general practice: preliminary 12 months’ results of a multifaceted
strategy (SMOCC). Centre for Quality of Care Research (WOK),
Maastricht/Nijmegen (2003)
Cost-effectiveness analyses of behavioral interventions
123
49. Schumann, A., Meyer, C., Rumpf, H.-J., Hanno¨ver, W., Hapke,
U., John, U.: Stage of change transitions and processes of change,
decisional balance and self-efficacy in smokers: A Transtheo-
retical model validation using longitudinal data. Psychol. Addict.
Behav. 19(1), 3–9 (2005). doi:10.1037/0893-164X.19.1.3
50. Schumann, A., John, U., Rumpf, H.-J., Hapke, U., Meyer, C.:
Change in the ‘‘stages of change’’ as outcome measures of a
smoking cessation intervention: a randomized controlled trial.
Prev. Med. 43, 101–106 (2006). doi:10.1016/j.ypmed.2006
.04.003
R. Prenger et al.
123
